Heidelberg Pharma Participates at Various Conferences
Heidelberg Pharma AG will present the company and its proprietary ATAC technology at several upcoming scientific and investor conferences. Heidelberg Pharma uses Amanitin as an innovative toxin to develop new cancer therapies that, when coupled to an antibody, can specifically kill even dormant cancer cells and overcome resistance. The first product candidate, HDP-101, is in clinical development for the treatment of multiple myeloma.
Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2021
Heidelberg Pharma AG today reported on the first nine months of fiscal year 2021 (1 December 2020 – 31 August 2021) and the Group’s financial figures.
Dr. Jan Schmidt-Brand, CEO and CFO of Heidelberg Pharma AG, commented: “We are delighted to have achieved important milestones in recent weeks and to have cleared several organizational hurdles for our initial clinical trial of HDP-101. The first two trial centers were initiated recently, and we are now eagerly awaiting the inclusion of the first patient.
Inside information pursuant to Article 17 MAR
Heidelberg Pharma AG Announces Adjustment of Guidance
Heidelberg Pharma AG today announced that it has adjusted its guidance for the current fiscal year published in March This is due to lower development expenses because clinical testing and manufacturing orders were delayed. Planned sales revenue from license agreements will not be recognized until the next fiscal year as some of the partners will reach milestones later than projected. Overall, the operating result will improve and funding requirements for fiscal year 2021 will decrease.
Heidelberg Pharma Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference and Participation at Various Conferences
Heidelberg Pharma AG today announced that they will present the company and its proprietary ATAC technology at several upcoming scientific and investor conferences. Heidelberg Pharma uses Amanitin as an innovative toxin to develop new cancer therapies that, when coupled to an antibody, can specifically kill even dormant cancer cells and overcome resistance. The candidate HDP-101 is about to enter clinical development for the treatment of multiple myeloma.
Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 in the US
Heidelberg Pharma AG today announced that preparations for the initiation of the Phase I/IIa clinical trial with HDP-101 have progressed and the initiation of the first study site, the MD Anderson Cancer Center, Houston, TX, US, is planned shortly.
Paul Ehrlich Institute Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101
Heidelberg Pharma AG today announced that the German authority Paul Ehrlich Institute, Langen, Germany, (PEI) has approved the study design of the planned Phase I/IIa clinical trial with the ATAC candidate HDP-101. HDP-101 is a BCMA antibody-Amanitin conjugate that will be tested in the indication multiple myeloma, a blood cancer with high unmet medical need.
Heidelberg Pharma Reports on First Half-Year 2021
Heidelberg Pharma AG today published its financial report on the first six months of 2021 (1 December 2020 – 31 May 2021).
Dr. Jan Schmidt-Brand, CEO and CFO of Heidelberg Pharma AG, commented: “FDA approval of the Phase I trial with HDP-101 was an important milestone for us as we move our first Antibody Targeted Amanitin Conjugate into clinical development. We were also able to raise EUR 20 million in a private placement to further advance our three proprietary ATAC programs. These are the next important steps for HDP-101: Approval of the study protocol for Germany by the Paul Ehrlich Institute and start of the trial in the US.
Heidelberg Pharma Announces Participation at Various Conferences
Heidelberg Pharma AG today announced that they will present its proprietary ATAC technology at two upcoming scientific events. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology, and to advance the biological mode of action of the toxin as a novel therapeutic principle.
Annual General Meeting 2021 of Heidelberg Pharma Approves All Proposed Resolutions
Heidelberg Pharma AG today announced that the shareholders of the Company approved the resolutions of the administration with large majorities (ranged from 98,40% to 99,99%) during the virtual Annual General Meeting today.
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2021
Heidelberg Pharma AG today reported on the first three months of fiscal year 2021 (1 December 2020 – 28 February 2021) and the Group’s financial figures.
dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz